North Bay
North Bay
North Bay, Ontario, Canada25 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria | Chronic Disease, Chronic Spontaneous Urticaria, Disease Attributes, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, chronic urticaria, immune system disorder, skin disorder, skin vascular disease, urticaria | Enrolling by invitation | Phase 3 | 2026-10-07 | NCT07256392 | |
| A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis | Cholangitis, Sclerosing, Digestive System Diseases, bile duct disorder, biliary tract disorder, cholangitis, primary sclerosing cholangitis | Recruiting | Phase 3 | 2026-10-01 | NCT07387549 | |
| A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Active, not recruiting | Phase 3 | 2026-09-25 | NCT05197049 | |
| Psoriasis Longitudinal Assessment and Registry | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, bone disorder, musculoskeletal system disorder, psoriasis, psoriatic arthritis, skin disorder, spondylitis, vertebral column disorder | Active, not recruiting | Not stated | 2026-09-25 | NCT00508547 | |
| Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) | Plaque Psoriasis | Recruiting | Phase 3 | 2026-09-22 | NCT07116967 | |
| A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Recruiting | Phase 4 | 2026-09-21 | NCT06095128 | |
| A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Recruiting | Phase 4 | 2026-09-09 | NCT06045754 | |
| A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Active, not recruiting | Phase 3 | 2026-08-14 | NCT03105102 | |
| A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Recruiting | Phase 2 | 2026-08-12 | NCT07037901 | |
| A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Active, not recruiting | Phase 3 | 2026-08-11 | NCT04232553 | |
| Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis | Plaque Psoriasis | Recruiting | Phase 2 | 2026-08-10 | NCT07474792 | |
| Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Enrolling by invitation | Phase 2 | 2026-07-29 | NCT07734415 | |
| Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis | Plaque Psoriasis | Active, not recruiting | Phase 2 | 2026-07-28 | NCT05739435 | |
| A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis | Plaque Psoriasis | Active, not recruiting | Phase 3 | 2026-06-02 | NCT06550076 | |
| Stopping Aminosalicylate Therapy in Inactive Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Active, not recruiting | Phase 4 | 2026-05-28 | NCT03261206 | |
| Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, psoriasis, skin disorder | Active, not recruiting | Phase 3 | 2026-04-13 | NCT06846541 | |
| Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD) | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Active, not recruiting | Phase 3 | 2026-04-13 | NCT04524611 | |
| A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Active, not recruiting | Phase 3 | 2026-04-09 | NCT03345823 | |
| A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) | Chronic Disease, Chronic Spontaneous Urticaria, Disease Attributes, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, chronic urticaria, immune system disorder, skin disorder, skin vascular disease, urticaria | Active, not recruiting | Phase 3 | 2026-03-25 | NCT06455202 | |
| A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Active, not recruiting | Phase 3 | 2026-01-20 | NCT03398135 | |
| Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice. | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Active, not recruiting | Not stated | 2025-07-17 | NCT05930275 | |
| An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD) | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Active, not recruiting | Not stated | 2025-05-09 | NCT05841537 | |
| SW-RCT Implementation of Canadian Syncope Risk Score Based Practice Recommendations | Consciousness Disorders, Disease Attributes, Emergencies, Neurobehavioral Manifestations, Neurologic Manifestations, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Syncope, Unconsciousness, nervous system disorder | Recruiting | Not applicable | 2025-03-27 | NCT04972071 | |
| An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Active, not recruiting | Not stated | 2025-02-28 | NCT05494606 | |
| Postexercise Hot-Water Immersion on Exercise Performance in Hypoxia | Exercise Training; Heat Exposure | Not yet recruiting | Not applicable | 2024-11-04 | NCT06672614 |